Compare DexCom, Inc. (DXCM) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Veritone Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: DexCom, Inc. is far larger — about 535.8× Veritone Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Veritone Inc for 12 Days on average.
| DXCM | VERI | |
|---|---|---|
Market Cap | $31.86B | $59.46M |
Volume | 3,607,070 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $92.34 | $8.39 |
52-Week Low | $54.84 | $0.59 |
Typical Hold Time | 62 Days | 12 Days |
Enterprise Value | $31.32B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Veritone (VERI) trades at $0.5647, down 18.31% over 24 hours, reflecting significant bearish pressure. The stock shows mixed signals with a bearish technical outlook but bullish oscillators. Fundamentally, the company reported a net loss of $111.73M in 2025 with a negative net income margin of -117.54%, though revenue remains near $92M. Recent developments include a $15M equity offering and partnerships with ATP Media and ZeroEyes, indicating ongoing business development efforts amidst financial challenges.
The outlook for VERI is highly speculative, with a consensus analyst price target of $3.75 suggesting substantial upside potential from current levels. However, persistent losses, negative cash flow from operations, and ongoing securities litigation pose significant risks. Investment appeal hinges on the company's ability to achieve profitability and monetize its AI solutions, making it suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
